Pluristem Therapeutics Inc. PSTI
Set alert
At close
52-week range unavailable
- Open
- 1.02
- Prev close
- 1.00
- Mkt cap
- 32.35M
- Vol
- 170.63K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.9595
- High
- 1.04
- Forward P/E
- -0.80
- Beta
- 1.91
- Short ratio
- 3.35
- Inst. own
- 12.80%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Sep 12, 2022
- 50-d avg
- 1.24
- 200-d avg
- 1.84
- 1y target
- 3.50
2Y chart
Events in this range
- Feb 7, 2022Earnings: —; estimate 0; surprise —%
- May 9, 2022Earnings: —; estimate 0; surprise —%
- Jul 20, 2022Rating: Alliance Global Partners · — → Buy
Signals (22)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Jul 13, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 21, 2022 | 4 years ago |
| MACD: Sell Signal | Jun 14, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 8, 2022 | 4 years ago |
| MACD: Sell Signal | Jun 2, 2022 | 4 years ago |
| MACD: Buy Signal | May 19, 2022 | 4 years ago |
| SMA: Bearish | Apr 14, 2022 | 4 years ago |
| SMA: Bullish | Apr 13, 2022 | 4 years ago |
| SMA: Bearish | Apr 12, 2022 | 4 years ago |
| MACD: Sell Signal | Apr 6, 2022 | 4 years ago |
| MACD: Buy Signal | Apr 5, 2022 | 4 years ago |
| MACD: Sell Signal | Apr 1, 2022 | 4 years ago |
| SMA: Bullish | Feb 28, 2022 | 4 years ago |
| MACD: Buy Signal | Feb 25, 2022 | 4 years ago |
| MACD: Sell Signal | Feb 24, 2022 | 4 years ago |
| MACD: Buy Signal | Feb 23, 2022 | 4 years ago |
| MACD: Sell Signal | Feb 22, 2022 | 4 years ago |
| MACD: Buy Signal | Jan 10, 2022 | 4 years ago |
| RSI: Oversold | Dec 27, 2021 | 4 years ago |
| RSI: Oversold | Dec 22, 2021 | 4 years ago |
| RSI: Oversold | Dec 20, 2021 | 4 years ago |
| RSI: Oversold | Dec 16, 2021 | 4 years ago |
Key statistics
- Market cap
- 32.35M
- Enterprise value
- 4.25M
- Trailing P/E
- 0.00
- Forward P/E
- -0.80
- PEG ratio
- 0.00
- Price / sales
- 138.24
- Price / book
- 0.85
- EPS (TTM)
- -1.46
- Beta
- 1.91
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 234.00K
- Revenue growth
- 0.00%
- Free cash flow
- -19.25M
- Total cash
- 61.98M
- Total debt
- 30.86M
- Return on equity
- -86.55%
- Shares outstanding
- 32.35M
- Short % of float
- 1.28%
- 50-day average
- 1.24
- 200-day average
- 1.84
Analyst view
Consensus: buy
- Target (low)
- 3.00
- Target (mean)
- 3.50
- Target (high)
- 4.00
- Strong buy0
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Sep 12, 2022
Expected Sep 12, 2022. Consensus EPS estimate -0.18.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Sep 12, 2022 | Jun 1, 2022 | -0.02 | — | — | — |
| May 9, 2022 | Mar 1, 2022 | 0.00 | — | — | — |
| Feb 7, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| May 6, 2021 | Mar 1, 2021 | 0.00 | — | — | — |
| Jul 6, 2020 | Mar 1, 2020 | -0.29 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 20, 2022 | Alliance Global Partners | main | — | Buy |
| May 4, 2021 | Alliance Global Partners | init | — | Buy |
| Dec 10, 2020 | Jefferies | down | Buy | Hold |
| Dec 10, 2020 | HC Wainwright & Co. | main | — | Buy |
| Nov 25, 2020 | Jefferies | main | — | Buy |
| Nov 25, 2020 | Jefferies | init | — | Buy |
About Pluristem Therapeutics Inc.
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- pluristem.com
News
- Pluristem (PSTI) Phase III Study Misses Goal, Stock Down
- Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery
- Stocks That Hit 52-Week Lows On Friday
- Best Penny Stocks to Buy as January Ends? 4 to Watch
- 45 Stocks Moving In Monday's Mid-Day Session
- Best Penny Stocks to Buy Right Now? 3 For Your List in January
- Biotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platform
- Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS
- Pluristem CEO Issues Shareholder Update
- Cathie Wood's ARK Invest Posts Fund Sales For Friday, Sept. 3, 2021: MCRB, DOCU, SHOP, SQ, TRMB, CLLS, PSTI, BABA, HDB
Your note
Sign in to keep a note on PSTI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABERMAN ZALMAN | Director | Purchase | Feb 9, 2022 | 0 |
| BEN-YORAM ISRAEL | Director | Purchase | Apr 7, 2019 | 798,485 |
| BIRGER PINHAS DORON | Director | Stock Award(Grant) | Jul 14, 2021 | 20,000 |
| BRAUN ISAAC | Director | Stock Award(Grant) | Sep 9, 2020 | 83,621 |
| CLOVER WOLF CAPITAL, LP | Beneficial Owner of more than 10% of a Class of Security | Sale | May 27, 2021 | 3,121,920 |
| GERMAIN MARK S | Director | Stock Award(Grant) | Sep 9, 2020 | 82,569 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Nia Impact Advisors, LLC | 2.59% | 837,898 | 837.90K | Mar 30, 2022 |
| Green Alpha Advisors, LLC | 2.51% | 812,539 | 812.54K | Jun 29, 2022 |
| Meitav Dash Investments Ltd | 0.52% | 167,593 | 167.59K | Mar 30, 2022 |
| Susquehanna International Group, LLP | 0.48% | 156,321 | 156.32K | Mar 30, 2022 |
| Jane Street Group, LLC | 0.42% | 137,468 | 137.47K | Mar 30, 2022 |
| Shelton Capital Management LLC | 0.40% | 128,532 | 128.53K | Mar 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Shelton Funds-Green Alpha Fund | 0.40% | 128,532 | 128.53K | May 30, 2022 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.22% | 70,000 | 70.00K | Mar 30, 2022 |
| SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF | 0.16% | 50,507 | 50.51K | Jun 29, 2022 |
| DFA International Core Equity Portfolio | 0.10% | 33,473 | 33.47K | Apr 29, 2022 |
| SPDR Portfolio Developed World ex-US ETF | 0.10% | 33,604 | 33.60K | May 30, 2022 |
| Fidelity NASDAQ Composite Index Fund | 0.08% | 25,169 | 25.17K | May 30, 2022 |